Exposure–Response Modeling in Adults and Adolescents With Schizophrenia to Support the Extrapolation of Brexpiprazole Efficacy to Adolescents.

In order to accelerate drug development and avoid unnecessary drug trials in vulnerable pediatric populations, the US Food and Drug Administration (FDA) released a general advice letter to sponsors permitting the effectiveness of atypical antipsychotics for the treatment of schizophrenia in adults t...

Descripción completa

Detalles Bibliográficos

Publicado en:	Journal of Clinical Pharmacology Vol. 64; no. 10; pp. 1236 - 1246
Autores principales:	Wang, Xiaofeng, Gopalakrishnan, Mathangi, Rich, Benjamin, Gobburu, Jogarao V., Larsen, Frank, Raoufinia, Arash
Formato:	equations & formulas research tables/charts Journal Article
Publicado:	Wiley-Blackwell Oct2024
Acceso en línea:	Ver este registro en EBSCOhost